Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Update

Protara Therapeutics, Inc. (NASDAQ:TARAGet Free Report) saw a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 61,400 shares, a decrease of 22.3% from the February 29th total of 79,000 shares. Based on an average trading volume of 75,500 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.7% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $23.00 target price on shares of Protara Therapeutics in a research report on Thursday, March 14th.

View Our Latest Analysis on Protara Therapeutics

Protara Therapeutics Price Performance

Protara Therapeutics stock opened at $4.01 on Monday. The firm has a 50-day moving average of $3.53 and a two-hundred day moving average of $2.30. Protara Therapeutics has a 1 year low of $1.04 and a 1 year high of $4.95.

Institutional Trading of Protara Therapeutics

A hedge fund recently bought a new stake in Protara Therapeutics stock. Virtu Financial LLC bought a new position in Protara Therapeutics, Inc. (NASDAQ:TARAFree Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 10,103 shares of the company’s stock, valued at approximately $30,000. Virtu Financial LLC owned 0.09% of Protara Therapeutics at the end of the most recent quarter. 38.13% of the stock is currently owned by institutional investors and hedge funds.

Protara Therapeutics Company Profile

(Get Free Report)

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease.

Recommended Stories

Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with's FREE daily email newsletter.